{"transactions":[{"id":1580192,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-12T22:35:59.000Z","date":"2024-03-11","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on January 1, 2025, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month."}],"balance_after":65000,"derivative":{"exercise_price":44.37,"expiration_date":"2034-03-10","underlying":"Common Shares","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0000950170-24-030233","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017024030233/ownership.xml","form_type":"4"}},{"id":1586006,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-08T22:31:41.000Z","date":"2024-03-07","kind":"exercise","planned":false,"acquired":false,"shares":7407,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the 1-for-4.86 reverse stock split of the Issuer's outstanding shares effected October 1, 2014 (the \"Reverse Stock Split\"). The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to this option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":9.85,"expiration_date":"2024-03-11","underlying":"Common Shares","underlying_shares":7407},"source":{"system":"sec-edgar","filing":"0000950170-24-028795","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017024028795/ownership.xml","form_type":"4"}},{"id":1586005,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-08T22:31:41.000Z","date":"2024-03-07","kind":"exercise","planned":false,"acquired":false,"shares":1234,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the 1-for-4.86 reverse stock split of the Issuer's outstanding shares effected October 1, 2014 (the \"Reverse Stock Split\"). The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to this option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":9.85,"expiration_date":"2024-03-11","underlying":"Common Shares","underlying_shares":1234},"source":{"system":"sec-edgar","filing":"0000950170-24-028795","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017024028795/ownership.xml","form_type":"4"}},{"id":1586004,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Common Shares","published_at":"2024-03-08T22:31:41.000Z","date":"2024-03-07","kind":"sale","planned":false,"acquired":false,"shares":6118,"price":46.3,"value":283263.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $46.25 to $46.36, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":8398,"source":{"system":"sec-edgar","filing":"0000950170-24-028795","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017024028795/ownership.xml","form_type":"4"}},{"id":1586003,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Common Shares","published_at":"2024-03-08T22:31:41.000Z","date":"2024-03-07","kind":"sale","planned":false,"acquired":false,"shares":1019,"price":46.15,"value":47026.85,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $46.15 to $46.17, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":14516,"source":{"system":"sec-edgar","filing":"0000950170-24-028795","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017024028795/ownership.xml","form_type":"4"}},{"id":1586002,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Common Shares","published_at":"2024-03-08T22:31:41.000Z","date":"2024-03-07","kind":"tax_withholding","planned":false,"acquired":false,"shares":1289,"price":45.96,"value":59242.44,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the closing price of the Company's common shares on March 6, 2024 for purposes of net settlement calculations."}],"balance_after":15535,"source":{"system":"sec-edgar","filing":"0000950170-24-028795","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017024028795/ownership.xml","form_type":"4"}},{"id":1586001,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Common Shares","published_at":"2024-03-08T22:31:41.000Z","date":"2024-03-07","kind":"exercise","planned":false,"acquired":true,"shares":7407,"price":9.85,"value":72958.95,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the 1-for-4.86 reverse stock split of the Issuer's outstanding shares effected October 1, 2014 (the \"Reverse Stock Split\"). The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise."}],"balance_after":16824,"source":{"system":"sec-edgar","filing":"0000950170-24-028795","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017024028795/ownership.xml","form_type":"4"}},{"id":1586000,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Common Shares","published_at":"2024-03-08T22:31:41.000Z","date":"2024-03-07","kind":"tax_withholding","planned":false,"acquired":false,"shares":215,"price":45.96,"value":9881.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the closing price of the Company's common shares on March 6, 2024 for purposes of net settlement calculations."}],"balance_after":9417,"source":{"system":"sec-edgar","filing":"0000950170-24-028795","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017024028795/ownership.xml","form_type":"4"}},{"id":1585999,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Common Shares","published_at":"2024-03-08T22:31:41.000Z","date":"2024-03-07","kind":"exercise","planned":false,"acquired":true,"shares":1234,"price":9.85,"value":12154.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the 1-for-4.86 reverse stock split of the Issuer's outstanding shares effected October 1, 2014 (the \"Reverse Stock Split\"). The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise."}],"balance_after":9632,"source":{"system":"sec-edgar","filing":"0000950170-24-028795","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017024028795/ownership.xml","form_type":"4"}},{"id":1696073,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Common Shares","published_at":"2024-01-02T21:41:00.000Z","date":"2023-12-29","kind":"other","planned":false,"acquired":false,"shares":8398,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were transferred to the Reporting Person's former spouse pursuant to the terms of a settlement agreement dated December 29, 2023 entered into in connection with the dissolution of the Reporting Person's marriage. The Reporting Person no longer reports as beneficially owned any securities owned by his former spouse."}],"balance_after":8398,"source":{"system":"sec-edgar","filing":"0000950170-24-000304","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017024000304/ownership.xml","form_type":"4"}},{"id":1953570,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-14T20:46:02.000Z","date":"2023-03-10","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on January 1, 2024 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month."}],"balance_after":75000,"derivative":{"exercise_price":34.18,"expiration_date":"2033-03-09","underlying":"Common Shares","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-23-018505","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919123018505/doc4.xml","form_type":"4"}},{"id":2167122,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-09-02T20:27:36.000Z","date":"2022-09-01","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":4.75,"expiration_date":"2028-03-11","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-22-048508","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919122048508/doc4.xml","form_type":"4"}},{"id":2167121,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-09-02T20:27:36.000Z","date":"2022-08-31","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":4.75,"expiration_date":"2028-03-11","underlying":"Common Shares","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-22-048508","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919122048508/doc4.xml","form_type":"4"}},{"id":2167120,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-09-02T20:27:36.000Z","date":"2022-08-31","kind":"exercise","acquired":false,"shares":17488,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":2.67,"expiration_date":"2022-12-31","underlying":"Common Shares","underlying_shares":17488},"source":{"system":"sec-edgar","filing":"0001209191-22-048508","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919122048508/doc4.xml","form_type":"4"}},{"id":2167119,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Common Shares","published_at":"2022-09-02T20:27:36.000Z","date":"2022-09-01","kind":"sale","acquired":false,"shares":8776,"price":38.8,"value":340508.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.73 to $38.88, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":16796,"source":{"system":"sec-edgar","filing":"0001209191-22-048508","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919122048508/doc4.xml","form_type":"4"}},{"id":2167118,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Common Shares","published_at":"2022-09-02T20:27:36.000Z","date":"2022-09-01","kind":"sale","acquired":false,"shares":35103,"price":38.03,"value":1334967.09,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $37.44 to $38.35, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":25572,"source":{"system":"sec-edgar","filing":"0001209191-22-048508","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919122048508/doc4.xml","form_type":"4"}},{"id":2167117,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Common Shares","published_at":"2022-09-02T20:27:36.000Z","date":"2022-09-01","kind":"tax_withholding","acquired":false,"shares":6121,"price":38.81,"value":237556.01,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the closing price of the Company's common shares on August 31, 2022 for purposes of net settlement calculations."}],"balance_after":60675,"source":{"system":"sec-edgar","filing":"0001209191-22-048508","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919122048508/doc4.xml","form_type":"4"}},{"id":2167116,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Common Shares","published_at":"2022-09-02T20:27:36.000Z","date":"2022-09-01","kind":"exercise","acquired":true,"shares":50000,"price":4.75,"value":237500.0,"ownership":{"direct":true},"balance_after":66796,"source":{"system":"sec-edgar","filing":"0001209191-22-048508","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919122048508/doc4.xml","form_type":"4"}},{"id":2167115,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Common Shares","published_at":"2022-09-02T20:27:36.000Z","date":"2022-08-31","kind":"sale","acquired":false,"shares":21352,"price":38.57,"value":823546.64,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.18 to $38.83, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":16796,"source":{"system":"sec-edgar","filing":"0001209191-22-048508","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919122048508/doc4.xml","form_type":"4"}},{"id":2167114,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Common Shares","published_at":"2022-09-02T20:27:36.000Z","date":"2022-08-31","kind":"tax_withholding","acquired":false,"shares":1572,"price":37.86,"value":59515.92,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the closing price of the Company's common shares on August 30, 2022 for purposes of net settlement calculations."}],"balance_after":38148,"source":{"system":"sec-edgar","filing":"0001209191-22-048508","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919122048508/doc4.xml","form_type":"4"}},{"id":2167113,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Common Shares","published_at":"2022-09-02T20:27:36.000Z","date":"2022-08-31","kind":"exercise","acquired":true,"shares":5000,"price":4.75,"value":23750.0,"ownership":{"direct":true},"balance_after":39720,"source":{"system":"sec-edgar","filing":"0001209191-22-048508","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919122048508/doc4.xml","form_type":"4"}},{"id":2167112,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Common Shares","published_at":"2022-09-02T20:27:36.000Z","date":"2022-08-31","kind":"exercise","acquired":true,"shares":17488,"price":2.67,"value":46692.96,"ownership":{"direct":true},"balance_after":34720,"source":{"system":"sec-edgar","filing":"0001209191-22-048508","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919122048508/doc4.xml","form_type":"4"}},{"id":2334880,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-14T20:21:52.000Z","date":"2022-03-10","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on January 1, 2023 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month."}],"balance_after":75000,"derivative":{"exercise_price":30.01,"expiration_date":"2032-03-09","underlying":"Common Shares","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-22-018463","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919122018463/doc4.xml","form_type":"4"}},{"id":2343711,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-09T00:35:30.000Z","date":"2022-03-04","kind":"exercise","acquired":false,"shares":6172,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"25% of the shares subject to the Option vested on the one year anniversary of January 1, 2012 (the \"Second 2012 Vesting Commencement Date\") and thereafter 1/48th of the shares subject to the Option vest on each monthly anniversary of the Second 2012 Vesting Commencement Date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period."}],"balance_after":0,"derivative":{"exercise_price":3.67,"expiration_date":"2022-03-10","underlying":"Common Shares","underlying_shares":6172},"source":{"system":"sec-edgar","filing":"0001209191-22-017318","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919122017318/doc4.xml","form_type":"4"}},{"id":2343710,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-09T00:35:30.000Z","date":"2022-03-04","kind":"exercise","acquired":false,"shares":1234,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/3 of the shares subject to the Option vested on January 1, 2012 (the \"First 2012 Vesting Commencement Date\") and thereafter the remaining 2/3 of the shares subject to the Option vest each monthly anniversary of the First 2012 Vesting Commencement Date over the following 4 years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period."}],"balance_after":0,"derivative":{"exercise_price":3.67,"expiration_date":"2022-03-10","underlying":"Common Shares","underlying_shares":1234},"source":{"system":"sec-edgar","filing":"0001209191-22-017318","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919122017318/doc4.xml","form_type":"4"}},{"id":2343709,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Common Shares","published_at":"2022-03-09T00:35:30.000Z","date":"2022-03-04","kind":"sale","acquired":false,"shares":5000,"price":30.23,"value":151150.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.15 to $30.33, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":17232,"source":{"system":"sec-edgar","filing":"0001209191-22-017318","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919122017318/doc4.xml","form_type":"4"}},{"id":2343708,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Common Shares","published_at":"2022-03-09T00:35:30.000Z","date":"2022-03-04","kind":"sale","acquired":false,"shares":5000,"price":31.05,"value":155250.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.78 to $31.07, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":22232,"source":{"system":"sec-edgar","filing":"0001209191-22-017318","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919122017318/doc4.xml","form_type":"4"}},{"id":2343707,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Common Shares","published_at":"2022-03-09T00:35:30.000Z","date":"2022-03-04","kind":"sale","acquired":false,"shares":5000,"price":30.15,"value":150750.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.10 to $31.17, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":27232,"source":{"system":"sec-edgar","filing":"0001209191-22-017318","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919122017318/doc4.xml","form_type":"4"}},{"id":2343706,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Common Shares","published_at":"2022-03-09T00:35:30.000Z","date":"2022-03-04","kind":"sale","acquired":false,"shares":6710,"price":30.56,"value":205057.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the closing price of the Company's common shares on March 3, 2022, which was converted to a Canadian dollar amount for purposes of net settlement calculations."}],"balance_after":32232,"source":{"system":"sec-edgar","filing":"0001209191-22-017318","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919122017318/doc4.xml","form_type":"4"}},{"id":2343705,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Common Shares","published_at":"2022-03-09T00:35:30.000Z","date":"2022-03-04","kind":"exercise","acquired":true,"shares":6172,"price":3.67,"value":22651.24,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise."}],"balance_after":38942,"source":{"system":"sec-edgar","filing":"0001209191-22-017318","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919122017318/doc4.xml","form_type":"4"}},{"id":2343704,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Common Shares","published_at":"2022-03-09T00:35:30.000Z","date":"2022-03-04","kind":"tax_withholding","acquired":false,"shares":696,"price":31.42,"value":21868.32,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the closing price of the Company's common shares on March 3, 2022, which was converted to a Canadian dollar amount for purposes of net settlement calculations."}],"balance_after":32770,"source":{"system":"sec-edgar","filing":"0001209191-22-017318","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919122017318/doc4.xml","form_type":"4"}},{"id":2343703,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Common Shares","published_at":"2022-03-09T00:35:30.000Z","date":"2022-03-04","kind":"exercise","acquired":true,"shares":1234,"price":3.67,"value":4528.78,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise."}],"balance_after":33466,"source":{"system":"sec-edgar","filing":"0001209191-22-017318","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919122017318/doc4.xml","form_type":"4"}},{"id":2688491,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-01T20:11:00.000Z","date":"2021-05-28","kind":"exercise","acquired":false,"shares":13374,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual\nexercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/3 of the shares subject to the Option vested on March 12, 2011 (the \"March 2011 Vesting Commencement Date\") and thereafter the remaining 2/3 of the shares subject to the Option vest each monthly anniversary of the March 2011 Vesting Commencement Date over the following 4 years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration\ndate falling during a Company blackout period and a lock-up agreement period."}],"balance_after":0,"derivative":{"exercise_price":3.85,"expiration_date":"2021-05-28","underlying":"Common Shares","underlying_shares":13374},"source":{"system":"sec-edgar","filing":"0001209191-21-036802","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919121036802/doc4.xml","form_type":"4"}},{"id":2688490,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-01T20:11:00.000Z","date":"2021-05-28","kind":"exercise","acquired":false,"shares":12345,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual\nexercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the Option vested on the one year anniversary of January 1, 2011 (the \"January 2011 Vesting Commencement Date\") and thereafter 1/48th of the shares subject to the Option vest on each monthly anniversary of the January 2011 Vesting Commencement Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration\ndate falling during a Company blackout period and a lock-up agreement period."}],"balance_after":0,"derivative":{"exercise_price":3.76,"expiration_date":"2021-05-28","underlying":"Common Shares","underlying_shares":12345},"source":{"system":"sec-edgar","filing":"0001209191-21-036802","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919121036802/doc4.xml","form_type":"4"}},{"id":2688489,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Common Shares","published_at":"2021-06-01T20:11:00.000Z","date":"2021-05-28","kind":"sale","acquired":false,"shares":2912,"price":18.81,"value":54774.72,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold.\nThese shares were sold in multiple transactions at prices ranging from $18.22 to $19.10, inclusive. The reporting person undertakes to provide to\nthe issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each\nseparate price within the range set forth herein"}],"balance_after":32232,"source":{"system":"sec-edgar","filing":"0001209191-21-036802","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919121036802/doc4.xml","form_type":"4"}},{"id":2688488,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Common Shares","published_at":"2021-06-01T20:11:00.000Z","date":"2021-05-28","kind":"sale","acquired":false,"shares":3155,"price":18.81,"value":59345.55,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold.\nThese shares were sold in multiple transactions at prices ranging from $18.22 to $19.10, inclusive. The reporting person undertakes to provide to\nthe issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each\nseparate price within the range set forth herein"}],"balance_after":35144,"source":{"system":"sec-edgar","filing":"0001209191-21-036802","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919121036802/doc4.xml","form_type":"4"}},{"id":2688487,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Common Shares","published_at":"2021-06-01T20:11:00.000Z","date":"2021-05-28","kind":"tax_withholding","acquired":false,"shares":2192,"price":18.91,"value":41450.72,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the closing price of the Company's common shares on May 27, 2021, which was converted to a Canadian dollar amount for\npurposes of net settlement calculations."}],"balance_after":38299,"source":{"system":"sec-edgar","filing":"0001209191-21-036802","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919121036802/doc4.xml","form_type":"4"}},{"id":2688486,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Common Shares","published_at":"2021-06-01T20:11:00.000Z","date":"2021-05-28","kind":"exercise","acquired":true,"shares":13374,"price":3.85,"value":51489.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual\nexercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise."}],"balance_after":40491,"source":{"system":"sec-edgar","filing":"0001209191-21-036802","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919121036802/doc4.xml","form_type":"4"}},{"id":2688485,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Common Shares","published_at":"2021-06-01T20:11:00.000Z","date":"2021-05-28","kind":"tax_withholding","acquired":false,"shares":2024,"price":18.91,"value":38273.84,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the closing price of the Company's common shares on May 27, 2021, which was converted to a Canadian dollar amount for\npurposes of net settlement calculations."}],"balance_after":27117,"source":{"system":"sec-edgar","filing":"0001209191-21-036802","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919121036802/doc4.xml","form_type":"4"}},{"id":2688484,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Common Shares","published_at":"2021-06-01T20:11:00.000Z","date":"2021-05-28","kind":"exercise","acquired":true,"shares":12345,"price":3.76,"value":46417.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual\nexercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise."}],"balance_after":29141,"source":{"system":"sec-edgar","filing":"0001209191-21-036802","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919121036802/doc4.xml","form_type":"4"}},{"id":2788741,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-15T20:43:52.000Z","date":"2021-03-12","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on January 1, 2022 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month."}],"balance_after":65000,"derivative":{"exercise_price":20.55,"expiration_date":"2031-03-11","underlying":"Common Shares","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-21-020481","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919121020481/doc4.xml","form_type":"4"}},{"id":3126396,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-02T21:40:30.000Z","date":"2020-06-01","kind":"exercise","acquired":false,"shares":8230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option fully vested on December 31, 2013. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period."}],"balance_after":0,"derivative":{"exercise_price":3.56,"expiration_date":"2020-06-02","underlying":"Common Shares","underlying_shares":8230},"source":{"system":"sec-edgar","filing":"0001209191-20-033669","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919120033669/doc4.xml","form_type":"4"}},{"id":3126395,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Common Shares","published_at":"2020-06-02T21:40:30.000Z","date":"2020-06-01","kind":"tax_withholding","acquired":false,"shares":1630,"price":13.7,"value":22331.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the closing price of the Company's common shares on May 29, 2020, which was converted to a Canadian dollar amount for purposes of net settlement calculations"}],"balance_after":16796,"source":{"system":"sec-edgar","filing":"0001209191-20-033669","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919120033669/doc4.xml","form_type":"4"}},{"id":3126394,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Common Shares","published_at":"2020-06-02T21:40:30.000Z","date":"2020-06-01","kind":"exercise","acquired":true,"shares":8230,"price":3.56,"value":29298.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise."}],"balance_after":18426,"source":{"system":"sec-edgar","filing":"0001209191-20-033669","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919120033669/doc4.xml","form_type":"4"}},{"id":3210390,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-13T21:09:07.000Z","date":"2020-03-12","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on January 1, 2021 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month."}],"balance_after":65000,"derivative":{"exercise_price":11.58,"expiration_date":"2030-03-11","underlying":"Common Shares","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-20-018963","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919120018963/doc4.xml","form_type":"4"}},{"id":3410487,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-09-18T23:41:19.000Z","date":"2019-09-16","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting over 36 months, in equal amounts, on the last day of each month."}],"balance_after":45000,"derivative":{"exercise_price":9.44,"expiration_date":"2029-09-15","underlying":"Common Shares","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001209191-19-050166","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919119050166/doc4.xml","form_type":"4"}},{"id":3414741,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-09-13T22:58:27.000Z","date":"2019-09-12","kind":"exercise","acquired":false,"shares":6172,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option fully vested on December 31, 2012. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3."}],"balance_after":0,"derivative":{"exercise_price":3.07,"expiration_date":"2019-09-18","underlying":"Common Shares","underlying_shares":6172},"source":{"system":"sec-edgar","filing":"0001209191-19-049538","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919119049538/doc4.xml","form_type":"4"}},{"id":3414740,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Common Shares","published_at":"2019-09-13T22:58:27.000Z","date":"2019-09-12","kind":"tax_withholding","acquired":false,"shares":1868,"price":9.38,"value":17521.84,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the closing price of the Company's common shares on September 11, 2019, which was converted to a Canadian dollar amount for purposes of net settlement calculations."}],"balance_after":10196,"source":{"system":"sec-edgar","filing":"0001209191-19-049538","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919119049538/doc4.xml","form_type":"4"}},{"id":3414739,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Strategy & Innovation"}}],"security":"Common Shares","published_at":"2019-09-13T22:58:27.000Z","date":"2019-09-12","kind":"exercise","acquired":true,"shares":6172,"price":3.07,"value":18948.04,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise."}],"balance_after":12064,"source":{"system":"sec-edgar","filing":"0001209191-19-049538","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919119049538/doc4.xml","form_type":"4"}},{"id":3991709,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Bus. & Corp. Development"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-03-16T20:33:26.000Z","date":"2018-03-15","kind":"exercise","acquired":false,"shares":3086,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option fully vested on December 31, 2011. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3."}],"balance_after":0,"derivative":{"exercise_price":3.77,"expiration_date":"2018-03-16","underlying":"Common Shares","underlying_shares":3086},"source":{"system":"sec-edgar","filing":"0001171843-18-002049","document":"formfoursherrington.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000117184318002049/formfoursherrington.xml","form_type":"4"}},{"id":3991708,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Bus. & Corp. Development"}}],"security":"Common Shares","published_at":"2018-03-16T20:33:26.000Z","date":"2018-03-15","kind":"tax_withholding","acquired":false,"shares":1928,"price":4.625,"value":8917.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the closing price of the Company's common shares on March 14, 2018, which was converted to a Canadian dollar amount for purposes of net settlement calculations."}],"balance_after":5892,"source":{"system":"sec-edgar","filing":"0001171843-18-002049","document":"formfoursherrington.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000117184318002049/formfoursherrington.xml","form_type":"4"}},{"id":3991707,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Bus. & Corp. Development"}}],"security":"Common Shares","published_at":"2018-03-16T20:33:26.000Z","date":"2018-03-15","kind":"exercise","acquired":true,"shares":3086,"price":3.77,"value":11634.22,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise."}],"balance_after":7820,"source":{"system":"sec-edgar","filing":"0001171843-18-002049","document":"formfoursherrington.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000117184318002049/formfoursherrington.xml","form_type":"4"}},{"id":3997565,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Bus. & Corp. Development"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-03-13T21:43:25.000Z","date":"2018-03-12","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on January 1, 2019, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month."}],"balance_after":55000,"derivative":{"exercise_price":4.75,"expiration_date":"2028-03-11","underlying":"Common Shares","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001171843-18-001915","document":"formfour.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000117184318001915/formfour.xml","form_type":"4"}},{"id":4181061,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Bus. & Corp. Development"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-10-24T22:46:59.000Z","date":"2017-10-23","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on October 23, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month."}],"balance_after":11000,"derivative":{"exercise_price":3.1,"expiration_date":"2027-10-22","underlying":"Common Shares","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001171843-17-006257","document":"formfour.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000117184317006257/formfour.xml","form_type":"4"}},{"id":4317746,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Bus. & Corp. Development"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-16T20:32:44.000Z","date":"2017-05-12","kind":"exercise","acquired":false,"shares":2057,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option fully vested on December 31, 2010."}],"balance_after":0,"derivative":{"exercise_price":3.21,"expiration_date":"2017-05-18","underlying":"Common Shares","underlying_shares":2057},"source":{"system":"sec-edgar","filing":"0001171843-17-003124","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000117184317003124/form4.xml","form_type":"4"}},{"id":4317745,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Bus. & Corp. Development"}}],"security":"Common Shares","published_at":"2017-05-16T20:32:44.000Z","date":"2017-05-12","kind":"tax_withholding","acquired":false,"shares":1345,"price":4.18,"value":5622.1,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the closing price of the Company's common shares on May 11, 2017, which was converted to a Canadian dollar amount for purposes of net settlement calculations."}],"balance_after":4734,"source":{"system":"sec-edgar","filing":"0001171843-17-003124","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000117184317003124/form4.xml","form_type":"4"}},{"id":4317744,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Bus. & Corp. Development"}}],"security":"Common Shares","published_at":"2017-05-16T20:32:44.000Z","date":"2017-05-12","kind":"exercise","acquired":true,"shares":2057,"price":3.21,"value":6602.97,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise."}],"balance_after":6079,"source":{"system":"sec-edgar","filing":"0001171843-17-003124","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000117184317003124/form4.xml","form_type":"4"}},{"id":4385916,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":93145,"kind":"person","name":"ROBIN SHERRINGTON","position":1,"cik":"0001619962","reported_name":"ROBIN SHERRINGTON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Bus. & Corp. Development"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-03-14T20:27:12.000Z","date":"2017-03-13","kind":"grant","acquired":true,"shares":27500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on January 1, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month."}],"balance_after":27500,"derivative":{"exercise_price":8.4,"expiration_date":"2027-03-12","underlying":"Common Shares","underlying_shares":27500},"source":{"system":"sec-edgar","filing":"0001171843-17-001508","document":"formfour.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000117184317001508/formfour.xml","form_type":"4"}}]}